Predictors of hematologic response and survival with stem cell transplantation in <scp>AL</scp> amyloidosis: A 25‐year longitudinal study
Joshua Gustine(Boston University), Vaishali Sanchorawala(Boston Medical Center), Lisa Mendelson(Boston University), Michelle Kaku(Boston University), Deepa M. Gopal(Boston University), Camille V. Edwards(Boston University), Andrea Havasi(Boston University), Tracy Joshi(Boston University), Raphaël Szalat(Boston University), K. H. Vincent Lau(Boston University), Andrew Staron(Boston University), Omar K. Siddiqi(Boston University), Frederick L. Ruberg(Boston University), J. Mark Sloan(Boston University), John L. Berk(Boston University)
Cited by 40
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k